Dr. David Fajgenbaum | CureTalks
"David Fajgenbaum, MD, MBA, MSc, FCPP, is an Assistant Professor of Medicine in the Division of Translational Medicine & Human Genetics at the University of Pennsylvania, Associate Director, Patient Impact of the University of Pennsylvania's Orphan Disease Center, Founding Director of the Castleman Disease Center at Penn, Co-Founder & volunteer Executive Director of the Castleman Disease Collaborative Network (CDCN), and Senior Fellow of the Leonard Davis Institute for Health Economics. Dr. Fajgenbaum leads the Castleman Research Program at Penn as PI of 18 translational research studies, including an international natural history study and the first-ever NIH R01-funded research of idiopathic multicentric Castleman disease (iMCD). His published research has changed the way iMCD is researched and treated. He is also an iMCD patient himself, who is in his longest remission ever thanks to a precision treatment that he identified, which had never been used before for iMCD."
Related Talks
Drug Repurposing for COVID-19 with CORONA Registry (COvid 19 Registry of Off-label & New Agents)
The global crisis due to COVID19 and the urgent need to identify effective therapeutics prompted Dr. David Fajgenbaum from the University of Pennsylvania…
Unraveling Castleman Disease
Dr. David Fajgenbaum was diagnosed with a rare disorder that killed 35% of patients within five years of diagnosis. Dr. Fajgenbaum realised that…